American Cancer Society | Strategic Alliance Partners

The European Commission has granted an expanded approval to ravulizumab-cwvz to include children with a body weight of at least 10 kg, as well as adolescents, with paroxysmal nocturnal hemoglobinuria.

For most of the pandemic, COVID-19 has been mild in children. Has this been true for children with underlying health conditions, in particular cancer?